Seattle, Washington, United States In 2016 was created Biomatics Capital Partners, which is appeared as VC. The main office of represented VC is situated in the Seattle. The company was established in North America in United States.
The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the Biomatics Capital Partners, startups are often financed by ARCH Venture Partners, Venrock, Asset Management Ventures (AMV). The meaningful sponsors for the fund in investment in the same round are GV, Tribeca Venture Partners, Pritzker Group Venture Capital. In the next rounds fund is usually obtained by ARCH Venture Partners, Tribeca Venture Partners, Sequoia Capital China.
This Biomatics Capital Partners works on 16 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. The top amount of exits for fund were in 2019. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 50 - 100 millions dollars. Considering the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations.
Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Health Care, Medical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline GRAIL, Denali Therapeutics, Verve Therapeutics
This organization was formed by Boris Nikolic, Julie Sunderland. Besides them, we counted 1 critical employee of this fund in our database.
Funds with similar focus
| Fund Name | Location |
| Angel Ventures Peru | Lima, Lima, Peru |
| Changxiang Entertainment | Beijing, China, Shijingshan |
| Citizens National Bank | Fort Worth, Texas, United States |
| CYCLEffect Regenerative Ventures | - |
| FacePaint | New York, New York, United States |
| FINOVA Capital | Arizona, Scottsdale, United States |
| FIS | Florida, Jacksonville, United States |
| Guava Capital | - |
| Hokkaido Venture Capital | Hokkaido Prefecture, Japan, Sapporo |
| Independence Blue Cross | Pennsylvania, Philadelphia, United States |
| Lafayette Group | United States, Vienna, Virginia |
| Nazca Ventures | - |
| Nest Tech | Chicago, Illinois, United States |
| Pemberstone Group | - |
| Sagene Tech Ventures | Norway, Oslo |
| Scor | France, Ile-de-France, Paris |
| Shenzhen Wangyu | China, Guangdong, Shenzhen |
| Tianantai Guquan Touzi | Beijing, Beijing, China |
| Yuku Guoji | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Encodia | $75M | 27 Jan 2021 | San Diego, California, United States | ||
Verve Therapeutics | $94M | 19 Jan 2021 | Cambridge, Massachusetts, United States | ||
Verve Therapeutics | $63M | 11 Jun 2020 | Cambridge, Massachusetts, United States | ||
Omniome | $60M | 09 Jan 2020 | San Diego, California, United States | ||
EGenesis | $100M | 07 Nov 2019 | Cambridge, Massachusetts, United States | ||
BlackThorn Therapeutics | $76M | 13 Jun 2019 | San Francisco, California, United States | ||
Thrive Earlier Detection | $110M | 30 May 2019 | Cambridge, Massachusetts, United States | ||
Verve Therapeutics | $58M | 07 May 2019 | Cambridge, Massachusetts, United States | ||
Omniome | $60M | 31 Jul 2018 | San Diego, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Encodia | $75M | 27 Jan 2021 | San Diego, California, United States | ||
Verve Therapeutics | $94M | 19 Jan 2021 | Cambridge, Massachusetts, United States | ||
Verve Therapeutics | $63M | 11 Jun 2020 | Cambridge, Massachusetts, United States | ||
Omniome | $60M | 09 Jan 2020 | San Diego, California, United States | ||
EGenesis | $100M | 07 Nov 2019 | Cambridge, Massachusetts, United States | ||
BlackThorn Therapeutics | $76M | 13 Jun 2019 | San Francisco, California, United States | ||
Thrive Earlier Detection | $110M | 30 May 2019 | Cambridge, Massachusetts, United States | ||
Verve Therapeutics | $58M | 07 May 2019 | Cambridge, Massachusetts, United States | ||
Omniome | $60M | 31 Jul 2018 | San Diego, California, United States |
